Gamida Cell Ltd. GMDA
We take great care to ensure that the data presented and summarized in this overview for Gamida Cell Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMDA
View allLatest Institutional Activity in GMDA
Top Purchases
Top Sells
About GMDA
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Insider Transactions at GMDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2024
|
Kenneth I Moch |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+46.26%
|
-
|
|
Jan 31
2024
|
Shawn Tomasello |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+45.25%
|
-
|
|
Jan 31
2024
|
Stephen T Wills |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+43.84%
|
-
|
|
Jan 31
2024
|
Ronit Simantov CMO & CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
480,319
+42.27%
|
-
|
|
Jan 31
2024
|
Julian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+32.06%
|
-
|
|
Jan 31
2024
|
Michele Ilene Korfin COO/CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
480,319
+40.59%
|
-
|
|
Jan 31
2024
|
Joshua F. Patterson GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
480,319
+35.96%
|
-
|
|
Jan 31
2024
|
Ivan M. Borrello |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+46.26%
|
-
|
|
Oct 19
2023
|
Abigail L. Jenkins President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
109,013
+22.52%
|
-
|
|
Aug 11
2023
|
Jeremy Blank Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+50.0%
|
-
|
|
Feb 08
2023
|
Michele Ilene Korfin COO/CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
92,990
+29.46%
|
-
|
|
Feb 08
2023
|
Joshua F. Patterson GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
63,000
+30.43%
|
-
|
|
Feb 08
2023
|
Ronit Simantov CMO & CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
58,100
+24.86%
|
-
|
|
Feb 08
2023
|
Shai Lankry Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,480
+27.97%
|
-
|
|
Feb 08
2023
|
Naama Halevi Davidov Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+46.7%
|
-
|
|
Feb 08
2023
|
Shawn Tomasello |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+40.27%
|
-
|
|
Feb 08
2023
|
Kenneth I Moch |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+46.7%
|
-
|
|
Feb 08
2023
|
Julian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+11.23%
|
-
|
|
Feb 08
2023
|
Ivan M. Borrello |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+46.7%
|
-
|
|
Feb 08
2023
|
Anat Cohen Dayag Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,300
+46.7%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.44M shares |
|---|